# Object Record 0
**objectId:** dashboard-item-1759853783245-patient-context
**type:** component
**componentType:** PatientContext
**description:** 
**content title:** Patient Context
**content component:** PatientContext
**content props patientData patient name:** Sarah Miller
**content props patientData patient date of birth:** 1981-06-03
**content props patientData patient age:** 43
**content props patientData patient sex:** Female
**content props patientData patient age at first encounter:** 43
**content props patientData patient identifiers mrn:** SM43850603
**content props patientData riskLevel:** high
**content props patientData primaryDiagnosis:** Severe Drug-Induced Liver Injury (Methotrexate-related)
**content props patientData problem list 0 name:** Type 2 Diabetes Mellitus
**content props patientData problem list 0 status:** active
**content props patientData problem list 1 name:** Essential Hypertension
**content props patientData problem list 1 status:** active
**content props patientData problem list 2 name:** Rheumatoid Arthritis
**content props patientData problem list 2 status:** active
**content props patientData problem list 3 name:** Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD/MASH)
**content props patientData problem list 3 status:** active
**content props patientData problem list 4 name:** Severe Methotrexate-induced Drug-Induced Liver Injury (DILI)
**content props patientData problem list 4 status:** active
**content props patientData problem list 5 name:** Acute jaundice episode (2024-08)
**content props patientData problem list 5 status:** resolved/improving
**content props patientData medication timeline 0 name:** Metformin
**content props patientData medication timeline 0 dose:** 1000 mg
**content props patientData medication timeline 0 route:** PO
**content props patientData medication timeline 0 frequency:** BD
**content props patientData medication timeline 0 start:** 2019-01-01
**content props patientData medication timeline 1 name:** Ramipril
**content props patientData medication timeline 1 dose:** 5 mg
**content props patientData medication timeline 1 route:** PO
**content props patientData medication timeline 1 frequency:** daily
**content props patientData medication timeline 1 start:** 2020-01-01
**content props patientData medication timeline 2 name:** Ibuprofen
**content props patientData medication timeline 2 dose:** variable
**content props patientData medication timeline 2 route:** PO
**content props patientData medication timeline 2 frequency:** PRN
**content props patientData medication timeline 2 start:** 2022-01-01
**content props patientData medication timeline 3 name:** Simethicone
**content props patientData medication timeline 3 dose:** standard
**content props patientData medication timeline 3 route:** PO
**content props patientData medication timeline 3 frequency:** PRN
**content props patientData medication timeline 3 start:** 2024-03-05
**content props patientData medication timeline 4 name:** Methotrexate
**content props patientData medication timeline 4 dose:** 7.5 mg
**content props patientData medication timeline 4 route:** PO
**content props patientData medication timeline 4 frequency:** weekly
**content props patientData medication timeline 4 start:** 2024-06-03
**content props patientData medication timeline 4 end:** 2024-08-12
**content props patientData medication timeline 5 name:** Folic Acid
**content props patientData medication timeline 5 dose:** 5 mg
**content props patientData medication timeline 5 route:** PO
**content props patientData medication timeline 5 frequency:** weekly
**content props patientData medication timeline 5 start:** 2024-06-03
**content props patientData medication timeline 6 name:** Methotrexate (dose reduced)
**content props patientData medication timeline 6 dose:** 5 mg
**content props patientData medication timeline 6 route:** PO
**content props patientData medication timeline 6 frequency:** weekly
**content props patientData medication timeline 6 start:** 2024-07-15
**content props patientData medication timeline 6 end:** 2024-08-12
**content props patientData medication timeline 7 name:** N-Acetylcysteine (NAC IV)
**content props patientData medication timeline 7 dose:** 3-bag protocol
**content props patientData medication timeline 7 route:** IV
**content props patientData medication timeline 7 frequency:** one-time protocol
**content props patientData medication timeline 7 start:** 2024-08-12
**content props patientData medication timeline 7 end:** 2024-08-17
**content props patientData medication timeline 8 name:** Ursodeoxycholic Acid (UDCA)
**content props patientData medication timeline 8 dose:** 500 mg
**content props patientData medication timeline 8 route:** PO
**content props patientData medication timeline 8 frequency:** BID
**content props patientData medication timeline 8 start:** 2024-08-15
**content props patientData allergies 0:** Methotrexate (severe DILI – permanent contraindication)
**createdAt:** 2025-10-14T16:16:23.245Z
**updatedAt:** 2025-10-14T16:16:23.245Z

# Object Record 1
**objectId:** dashboard-item-1759906076097-medication-timeline
**type:** component
**componentType:** MedicationTimeline
**description:** 
**content title:** Medication Timeline
**content component:** MedicationTimeline
**content props encounters 0 encounter no:** 1
**content props encounters 0 date:** 2024-03-05
**content props encounters 0 type:** General Practice
**content props encounters 0 provider:** Dr. P. Stevens
**content props encounters 0 diagnosis:** Fatigue; Suboptimally controlled T2DM/HTN; RA stable
**content props encounters 0 medications 0:** Metformin 1000mg BD
**content props encounters 0 medications 1:** Ramipril 5mg daily
**content props encounters 0 medications 2:** Ibuprofen PRN
**content props encounters 0 medications 3:** Simethicone PRN
**content props encounters 0 notes:** Initial evaluation; abnormal ALT 78 U/L; lifestyle counselling; HbA1c 58 mmol/mol.
**content props encounters 1 encounter no:** 2
**content props encounters 1 date:** 2024-04-01
**content props encounters 1 type:** General Practice
**content props encounters 1 provider:** Dr. P. Stevens
**content props encounters 1 diagnosis:** Review of elevated ALT; suspected MASLD; RA requiring MTX evaluation
**content props encounters 1 medications 0:** Metformin 1000mg BD
**content props encounters 1 medications 1:** Ramipril 5mg daily
**content props encounters 1 medications 2:** Ibuprofen PRN
**content props encounters 1 medications 3:** Simethicone PRN
**content props encounters 1 notes:** Deferred Methotrexate; ordered hepatitis/autoimmune/metabolic workup.
**content props encounters 2 encounter no:** 3
**content props encounters 2 date:** 2024-05-06
**content props encounters 2 type:** General Practice
**content props encounters 2 provider:** Dr. P. Stevens
**content props encounters 2 diagnosis:** LFT normalization; RA requiring DMARD; MASLD flare resolved
**content props encounters 2 medications 0:** Methotrexate 7.5mg weekly (planned start 2024-06-03)
**content props encounters 2 medications 1:** Folic Acid 5mg weekly
**content props encounters 2 medications 2:** Metformin 1000mg BD
**content props encounters 2 medications 3:** Ramipril 5mg daily
**content props encounters 2 medications 4:** Ibuprofen PRN
**content props encounters 2 medications 5:** Simethicone PRN
**content props encounters 2 notes:** Cleared for MTX; full hepatitis, autoimmune, metabolic workup negative.
**content props encounters 3 encounter no:** 4
**content props encounters 3 date:** 2024-06-03
**content props encounters 3 type:** General Practice
**content props encounters 3 provider:** Dr. P. Stevens
**content props encounters 3 diagnosis:** Initiation of Methotrexate therapy for RA
**content props encounters 3 medications 0:** Methotrexate 7.5mg weekly (started today)
**content props encounters 3 medications 1:** Folic Acid 5mg weekly
**content props encounters 3 medications 2:** Metformin 1000mg BD
**content props encounters 3 medications 3:** Ramipril 5mg daily
**content props encounters 3 notes:** MTX started; monitoring schedule established (LFT/FBC q6 weeks).
**content props encounters 4 encounter no:** 5
**content props encounters 4 date:** 2024-07-15
**content props encounters 4 type:** General Practice
**content props encounters 4 provider:** Dr. P. Stevens
**content props encounters 4 diagnosis:** Severe hepatocellular DILI from Methotrexate; RA symptoms improving
**content props encounters 4 medications 0:** Methotrexate reduced to 5mg weekly
**content props encounters 4 medications 1:** Folic Acid 5mg weekly
**content props encounters 4 medications 2:** Metformin 1000mg BD
**content props encounters 4 medications 3:** Ramipril 5mg daily
**content props encounters 4 notes:** ALT 185 U/L (~4.6× ULN); MTX dose reduced (though standard is to stop); hepatology referral placed.
**content props encounters 5 encounter no:** 6
**content props encounters 5 date:** 2024-08-12
**content props encounters 5 type:** Emergency Department
**content props encounters 5 provider:** ED team + handover from Dr. Stevens
**content props encounters 5 diagnosis:** Severe acute DILI with cholestasis; jaundice; bilirubin 110 μmol/L
**content props encounters 5 medications 0:** Methotrexate stopped
**content props encounters 5 medications 1:** N-Acetylcysteine (NAC) IV protocol initiated
**content props encounters 5 notes:** Urgent hospitalization; ALT 490 U/L (12× ULN); NAC started; admitted to hepatology ward.
**content props encounters 6 encounter no:** 7
**content props encounters 6 date:** 2024-08-15
**content props encounters 6 type:** Inpatient Hepatology
**content props encounters 6 provider:** Dr. R. Sharma (Consultant Hepatologist)
**content props encounters 6 diagnosis:** Severe MTX-induced DILI with MASH; improving ALT; worsening jaundice
**content props encounters 6 medications 0:** NAC protocol (continuing until 2024-08-17)
**content props encounters 6 medications 1:** Ursodeoxycholic Acid (UDCA) 500mg BID
**content props encounters 6 medications 2:** Folic Acid (continued)
**content props encounters 6 notes:** Methotrexate added to permanent contraindication list; ALT decreasing to 420; bilirubin rising to 190.
**content props medicationTimeline 0 name:** Metformin
**content props medicationTimeline 0 startDate:** 2019-01-01
**content props medicationTimeline 0 dose:** 1000mg BD
**content props medicationTimeline 0 indication:** Type 2 Diabetes Mellitus
**content props medicationTimeline 1 name:** Ramipril
**content props medicationTimeline 1 startDate:** 2020-01-01
**content props medicationTimeline 1 dose:** 5mg daily
**content props medicationTimeline 1 indication:** Hypertension
**content props medicationTimeline 2 name:** Ibuprofen
**content props medicationTimeline 2 startDate:** 2022-01-01
**content props medicationTimeline 2 dose:** PRN
**content props medicationTimeline 2 indication:** Rheumatoid arthritis pain
**content props medicationTimeline 3 name:** Simethicone
**content props medicationTimeline 3 startDate:** 2024-03-05
**content props medicationTimeline 3 dose:** PRN
**content props medicationTimeline 3 indication:** Bloating/gas symptoms
**content props medicationTimeline 4 name:** Methotrexate
**content props medicationTimeline 4 startDate:** 2024-06-03
**content props medicationTimeline 4 endDate:** 2024-07-15
**content props medicationTimeline 4 dose:** 7.5mg weekly
**content props medicationTimeline 4 indication:** Rheumatoid Arthritis
**content props medicationTimeline 5 name:** Methotrexate
**content props medicationTimeline 5 startDate:** 2024-07-15
**content props medicationTimeline 5 endDate:** 2024-08-12
**content props medicationTimeline 5 dose:** 5mg weekly
**content props medicationTimeline 5 indication:** Rheumatoid Arthritis (dose reduction due to hepatotoxicity)
**content props medicationTimeline 6 name:** Folic Acid
**content props medicationTimeline 6 startDate:** 2024-06-03
**content props medicationTimeline 6 dose:** 5mg weekly
**content props medicationTimeline 6 indication:** MTX toxicity prophylaxis
**content props medicationTimeline 7 name:** N-Acetylcysteine (IV)
**content props medicationTimeline 7 startDate:** 2024-08-12
**content props medicationTimeline 7 endDate:** 2024-08-17
**content props medicationTimeline 7 dose:** 3-bag IV protocol
**content props medicationTimeline 7 indication:** Acute severe DILI
**content props medicationTimeline 8 name:** Ursodeoxycholic Acid (UDCA)
**content props medicationTimeline 8 startDate:** 2024-08-15
**content props medicationTimeline 8 dose:** 500mg BID
**content props medicationTimeline 8 indication:** Cholestasis/jaundice
**createdAt:** 2025-10-14T16:47:56.098Z
**updatedAt:** 2025-11-18T09:15:31.732Z

# Object Record 28
**objectId:** dashboard-item-1763617711104-scheduling-panel
**type:** component
**componentType:** SchedulingPanel
**description:** Integrated scheduling and investigation ordering panel
**content title:** Care Coordination & Scheduling
**content component:** SchedulingPanel
**content props patientId:** SM43850603
**content props currentStatus:** Post-Acute Discharge (Stable)
**content props schedulingContext nextAvailableSlot date:** 2025-12-15T09:30:00
**content props schedulingContext nextAvailableSlot provider:** Dr. R. Sharma (Hepatology) & Dr. R. Hall (Rheumatology)
**content props schedulingContext nextAvailableSlot clinicType:** Joint Liver/Rheum Complexity Clinic
**content props schedulingContext nextAvailableSlot location:** Outpatient Zone C, Room 12
**content props schedulingContext nextAvailableSlot wait time:** ~4 weeks
**content props schedulingContext outstandingInvestigations 0 id:** INV-FS-001
**content props schedulingContext outstandingInvestigations 0 name:** Transient Elastography (Fibroscan)
**content props schedulingContext outstandingInvestigations 0 status:** Pending Request
**content props schedulingContext outstandingInvestigations 0 priority:** Routine (6-month post-injury check)
**content props schedulingContext outstandingInvestigations 0 notes:** Assess for residual fibrosis following June 2025 DILI event
**content props schedulingContext outstandingInvestigations 1 id:** INV-VS-002
**content props schedulingContext outstandingInvestigations 1 name:** Confirmatory Viral Serology (Repeat)
**content props schedulingContext outstandingInvestigations 1 status:** Pending Request
**content props schedulingContext outstandingInvestigations 1 priority:** Routine
**content props schedulingContext outstandingInvestigations 1 notes:** Final exclusion of occult viral hepatitis
**content props schedulingContext bookingAction status:** Confirmed
**content props schedulingContext bookingAction lastUpdated:** 2025-11-20T10:05:00Z
**content props schedulingContext bookingAction actionsTaken 0:** Slot secured: 2025-12-15 @ 09:30
**content props schedulingContext bookingAction actionsTaken 1:** Fibroscan request generated (Accession #FS-251215-09)
**content props schedulingContext bookingAction actionsTaken 2:** Invitation letter generated and sent via Patient Portal
**content props schedulingContext bookingAction correspondencePreview:** Dear Sarah Miller, your follow-up appointment for Liver Function Review has been scheduled for December 15, 2025...
**createdAt:** 2025-11-20T05:48:31.409Z
**updatedAt:** 2025-11-20T05:48:38.225Z

# Object Record 0
**objectId:** dashboard-item-1759906300003-single-encounter-1
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #1 - Outpatient Visit
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 1
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-03-05T10:15:22Z
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** General Practice
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Suboptimal control of T2DM/HTN, Chronic Fatigue Syndrome possibly related to MASLD. Diabetes control is poor with HbA1c at 58 mmol/mol, indicating long-standing hyperglycaemia and need for therapeutic adjustment.
**content props encounter assessment differential 0:** T2DM suboptimal control
**content props encounter assessment differential 1:** Hypertension suboptimal control
**content props encounter assessment differential 2:** Chronic Fatigue Syndrome
**content props encounter assessment differential 3:** MASLD
**content props encounter chief complaint:** Increased fatigue over the past 4-5 months
**content props encounter hpi:** Sarah Miller, a 43-year-old administrative assistant, presents with debilitating fatigue affecting work performance. She averages 6.5 hours of non-restorative sleep per night and experiences RA-related discomfort, particularly in the right wrist. She takes Ibuprofen 4-5 times per week for pain and chemically-induced frequent bloating. HbA1c from today’s labs is 58 mmol/mol, confirming persistently weak glycaemic control which may be contributing to fatigue and metabolic strain.
**content props encounter medications prior 0 name:** Metformin
**content props encounter medications prior 0 route:** Oral, unknown dose, BD frequency, for T2DM
**content props encounter medications prior 1 name:** Ramipril
**content props encounter medications prior 1 route:** Oral, 5mg, OD frequency, for Hypertension
**content props encounter medications prior 2 name:** Ibuprofen
**content props encounter medications prior 2 route:** Oral, unknown dose, taken 4-5 times per week for RA pain
**content props encounter medications prior 3 name:** Simethicone
**content props encounter medications prior 3 route:** Oral, unknown dose, unknown frequency, for bloating
**content props encounter physical exam general:** Appears non-toxic and well-perfused.
**content props encounter physical exam msk:** Mild effusion in right MCP joint 3, mild pain on movement.
**content props encounter physical exam other systems:** Vital Signs: BP 146/92 mmHg (sitting), HR 82 bpm, RR 16/min, Temp 36.8°C, SpO₂ 99% on room air. Anthropometrics: Height 1.64 m, Weight 86 kg (BMI 32.0 kg/m²; class I obesity). Weight reported as broadly stable over the past 12 months. Skin/Sclera: Anicteric sclerae; no chronic liver disease stigmata. Abdomen: Soft, lax, normal liver span, no tenderness. Diabetes: Persistent hyperglycaemia suspected based on elevated HbA1c and obesity.
**content props encounter plan investigations labs 0:** Complete LFTs
**content props encounter plan investigations labs 1:** HbA1c
**content props encounter plan investigations labs 2:** Consider future intensification of diabetes therapy if HbA1c remains > 53 mmol/mol
**content props encounter plan management follow up:** Follow-up in 4 weeks to evaluate LFTs and MTX eligibility.
**content props encounter reason for visit:** Increased fatigue
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 1
**content props dataSource:** Electronic Health Record
**createdAt:** 2025-10-14T16:55:00.003Z
**updatedAt:** 2025-10-14T16:55:00.003Z

# Object Record 4
**objectId:** dashboard-item-1759906300004-single-encounter-5
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #5 - Outpatient
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 5
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-07-15T14:00:30
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** Rheumatology
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Methotrexate-induced Drug-Induced Liver Injury (DILI) presenting with elevated ALT (185 U/L, 4.6x ULN), with new intermittent nausea and increased fatigue. Rheumatoid arthritis symptoms are improving on Methotrexate. Diabetes control has deteriorated with HbA1c rising to 60 mmol/mol, signalling worsening glycaemia during MTX therapy and possible contribution to fatigue.
**content props encounter assessment differential 0:** Methotrexate-induced Drug-Induced Liver Injury (DILI)
**content props encounter assessment differential 1:** Underlying MASLD risk factors
**content props encounter chief complaint:** Routine Methotrexate (MTX) monitoring. Reports of new intermittent nausea and increased fatigue.
**content props encounter hpi:** Sarah Miller, a 43-year-old female, presents for routine Methotrexate monitoring. She reports ~1 kg unintentional weight loss over the past month, attributed to reduced appetite and intermittent nausea, primarily in the evenings. No vomiting or diarrhea. Fatigue levels have returned to pre-MTX initiation severity. Rheumatoid arthritis symptoms have significantly improved with diminished joint pain and increased daily function since starting Methotrexate. Recent labs show ALT elevated to 185 U/L (4.6x ULN). HbA1c has worsened to 60 mmol/mol, indicating declining diabetes control despite weight loss.
**content props encounter physical exam general:** Vital Signs: BP 144/92 mmHg (sitting), HR 88 bpm, RR 16/min, Temp 36.8°C, SpO₂ 98% on room air.
**content props encounter physical exam msk:** Joint pain has diminished.
**content props encounter physical exam other systems:** Weight 83 kg (BMI 30.8 kg/m²). Despite some weight reduction, diabetes control is worsening with higher HbA1c and increased metabolic fatigue.
**content props encounter plan investigations labs 0:** Repeat liver function tests in four weeks
**content props encounter plan investigations labs 1:** HbA1c monitoring recommended due to recent deterioration
**content props encounter plan management follow up:** Follow up in four weeks. Advised to remain vigilant for any worsening of symptoms or new signs of liver dysfunction such as jaundice, further exacerbated fatigue, or darker urine. Ensure adherence to adjusted Methotrexate regimen. Attend Hepatology consultation.
**content props encounter plan management medications started 0 dose:** 5mg
**content props encounter plan management medications started 0 frequency:** weekly
**content props encounter plan management medications started 0 name:** Methotrexate
**content props encounter plan management medications started 0 route:** 
**content props encounter reason for visit:** Routine Methotrexate monitoring and management of new symptoms of nausea and fatigue, and elevated liver enzymes.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 5
**content props dataSource:** Nervecentre
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 6
**objectId:** dashboard-item-1759906300004-single-encounter-7
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #7 - Inpatient Hepatology Ward B
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 7
**content props encounter meta visit type:** Inpatient
**content props encounter meta date time:** 2024-08-15T10:00:48
**content props encounter meta provider name:** Dr. R. Sharma
**content props encounter meta provider specialty:** Consultant Hepatologist
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Severe Drug-Induced Liver Injury (DILI) secondary to Methotrexate, with a RUCAM score of 9/10, indicating a high likelihood of causation. No features of Acute-on-Chronic Liver Failure (ACLF). Underlying Metabolic Associated Steatotic Hepatitis (MASH).
**content props encounter chief complaint:** Severe Drug-Induced Liver Injury (DILI)
**content props encounter hpi:** The patient is reviewed on Day 3 of her hospital admission following severe DILI. Methotrexate was stopped immediately upon recognizing it as the causative agent. Sarah remains significantly jaundiced; however, nausea has shown slight improvement since admission. Vital neurological signs include a stable Glasgow Coma Scale (GCS) score of 15, with no evidence of hepatic encephalopathy (HE); absence of asterixis or cognitive impairment. The ALT level, though elevated at 420 U/L, is beginning to decline, suggesting a positive response to the cessation of Methotrexate. Crucially, the INR remains stable at 1.1, indicating preserved liver synthetic function. These clinical findings collectively confirm a diagnosis of severe, cholestatic DILI in a patient with underlying Metabolic Associated Steatotic Hepatitis (MASH), markedly susceptible to hepatotoxic insults.
**content props encounter physical exam general:** Sarah exhibits pronounced jaundice, evidenced by a total bilirubin level of 190 μmol/L. Despite this, she appears alert and reports moderate comfort under current care measures. Vital Signs (ward review): BP 128/82 mmHg, HR 96 bpm, RR 16/min, Temp 37.0°C, SpO₂ 97% on room air. Anthropometrics: Weight 81 kg (BMI 30.1 kg/m²). No significant interval weight change since admission.
**content props encounter physical exam msk:** 
**content props encounter physical exam other systems:** CNS Examination: She is fully oriented, demonstrating no neurological deficits. GCS remains a reassuring 15 with negative neurological signs including asterixis, tremor, and speech abnormalities. Cardio/Pulmonary: Vital signs are stable with no indications of fluid overload, pulmonary distress, or hepatorenal syndrome. Abdominal Examination: The abdomen is soft and non-tender. The liver edge is not easily palpable due to Sarah's body habitus, yet no tenderness is detected upon examination.
**content props encounter plan investigations imaging 0:** Fibroscan in three months
**content props encounter plan investigations labs 0:** Daily INR evaluations until ALT levels fall below 150 U/L
**content props encounter plan investigations labs 1:** Neurological assessments every four hours
**content props encounter plan management follow up:** Arrange a Fibroscan (Liver Stiffness Measurement) in three months to assess fibrosis arising from chronic MASH and the acute DILI event. Coordinate with Rheumatology for the initiation of a non-hepatotoxic DMARD alternative, such as Hydroxychloroquine or a biologic, to manage RA without compromising liver health.
**content props encounter plan management medications started 0 dose:** 500mg
**content props encounter plan management medications started 0 frequency:** twice daily
**content props encounter plan management medications started 0 name:** Ursodeoxycholic Acid (UDCA)
**content props encounter plan management medications started 0 route:** 
**content props encounter plan management medications started 1 dose:** 
**content props encounter plan management medications started 1 frequency:** 
**content props encounter plan management medications started 1 name:** Folic Acid
**content props encounter plan management medications started 1 route:** 
**content props encounter reason for visit:** Review on Day 3 of hospital admission following severe DILI.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 7
**content props dataSource:** Nervecentre
**createdAt:** 2025-10-14T16:55:00.004Z
**updatedAt:** 2025-10-14T16:55:00.004Z

# Object Record 2
**objectId:** dashboard-item-1759906300004-single-encounter-3
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #3 - Outpatient Follow-up
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 3
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-05-06T09:00:10
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** Unknown
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Follow-up regarding normalization of liver function tests and initiation of Methotrexate for rheumatoid arthritis management. Normalization of LFTs with ALT at 35 U/L. Negative workup for chronic liver conditions. Likely transient elevation possibly related to MASLD. Cleared for Methotrexate initiation.
**content props encounter assessment differential 0:** Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
**content props encounter assessment differential 1:** Acute self-limiting liver episode
**content props encounter chief complaint:** Follow-up regarding normalization of liver function tests (LFTs) and potential initiation of Methotrexate for rheumatoid arthritis management.
**content props encounter hpi:** Since the previous review, Sarah reports increased adherence to dietary advice and gentle walking most days, noting a ~1.5 kg weight loss since March. Comprehensive hepatitis workup (viral, autoimmune, metabolic) returned negative. ALT has decreased to 35 U/L, suggesting transient elevation. Patient is considered low-risk for MTX initiation.
**content props encounter physical exam general:** Vital Signs: BP 140/88 mmHg (sitting), HR 78 bpm, RR 15/min, Temp 36.6°C, SpO₂ 99% on room air.
**content props encounter physical exam msk:** 
**content props encounter physical exam other systems:** Anthropometrics: Weight 84 kg (BMI 31.2 kg/m²).
**content props encounter plan investigations labs 0:** LFTs every 6 weeks
**content props encounter plan investigations labs 1:** FBC every 6 weeks
**content props encounter plan management follow up:** Follow-up appointment set for early August to review treatment response, adherence to monitoring, and adjust plan. Instructed to begin Methotrexate on 2024-06-03. Emphasized adherence to strict 6-weekly monitoring schedule.
**content props encounter plan management medications started 0 dose:** 7.5mg
**content props encounter plan management medications started 0 frequency:** weekly
**content props encounter plan management medications started 0 name:** Methotrexate
**content props encounter plan management medications started 0 route:** Unknown
**content props encounter plan management medications started 1 dose:** 5mg
**content props encounter plan management medications started 1 frequency:** weekly
**content props encounter plan management medications started 1 name:** Folic acid
**content props encounter plan management medications started 1 route:** Unknown
**content props encounter reason for visit:** Follow-up for liver function tests and rheumatoid arthritis management.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 3
**content props dataSource:** Electronic Health Record
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 3
**objectId:** dashboard-item-1759906300004-single-encounter-4
**type:** component
**componentType:** SingleEncounterDocument
**description:** 
**content title:** Encounter #4 - Outpatient
**content component:** SingleEncounterDocument
**content props encounter encounter no:** 4
**content props encounter meta visit type:** Outpatient
**content props encounter meta date time:** 2024-06-03T11:30:55
**content props encounter meta provider name:** Dr. P. Stevens
**content props encounter meta provider specialty:** Unknown
**content props encounter meta ui risk color:** yellow
**content props encounter assessment impression:** Initiation of Methotrexate for Rheumatoid Arthritis management.
**content props encounter chief complaint:** Initiation of Disease-Modifying Anti-Rheumatic Drug (DMARD) - Methotrexate (MTX) for Rheumatoid Arthritis (RA) management.
**content props encounter hpi:** Sarah Miller presents for the initiation of Methotrexate treatment for RA. She reports her joint pain has been stable but remains a significant source of discomfort, affecting her daily activities. A thorough review of her medical history, medication adherence, and lifestyle was conducted. The patient confirms receipt and comprehension of the Methotrexate informational leaflet, indicating understanding of the treatment regimen and potential adverse effects. The decision to commence Methotrexate was made following normalization of liver function tests (LFTs) as of May 6, 2024. The patient reiterated understanding of the importance of strict compliance with the monitoring schedule due to the severe hepatotoxicity risk associated with Methotrexate.
**content props encounter physical exam general:** Vital Signs: BP 138/86 mmHg (sitting), HR 80 bpm, RR 15/min, Temp 36.7°C, SpO₂ 98% on room air. Anthropometrics: Weight 84 kg (BMI 31.2 kg/m²). Weight stable compared with early May.
**content props encounter physical exam msk:** 
**content props encounter physical exam other systems:** 
**content props encounter plan investigations labs 0:** LFTs every six weeks
**content props encounter plan investigations labs 1:** Full Blood Count (FBC) every six weeks
**content props encounter plan management follow up:** First LFT/FBC evaluation scheduled for July 15, 2024. Regular monitoring every six weeks for the next 6 months. Patient to contact clinic immediately if severe nausea, vomiting, or jaundice occur.
**content props encounter plan management medications started 0 dose:** 7.5mg
**content props encounter plan management medications started 0 frequency:** once weekly
**content props encounter plan management medications started 0 name:** Methotrexate
**content props encounter plan management medications started 0 route:** orally
**content props encounter plan management medications started 1 dose:** 5mg
**content props encounter plan management medications started 1 frequency:** weekly
**content props encounter plan management medications started 1 name:** Folic Acid
**content props encounter plan management medications started 1 route:** orally
**content props encounter reason for visit:** Initiation of Methotrexate for Rheumatoid Arthritis management.
**content props patient name:** Sarah Miller
**content props patient sex:** Female
**content props patient age at first encounter:** 43
**content props encounterIndex:** 4
**content props dataSource:** Medilogik
**createdAt:** 2025-10-15T08:00:00.000Z
**updatedAt:** 2025-10-15T08:00:00.000Z

# Object Record 16
**objectId:** raw-nervecentre-encounter-3
**type:** component
**componentType:** RawClinicalNote
**description:** Nervecentre Encounter 3 - Critical Inpatient Alert with Highlights
**content title:** Nervecentre - Encounter 3
**content component:** RawClinicalNote
**content props encounterNumber:** 7
**content props date:** 2024-09-02
**content props visitType:** Outpatient
**content props provider:** Dr. K. Hussain
**content props specialty:** AMU SHO
**content props rawText:** 
### **Nervecentre**

**Module:** Laboratory Alerting, Inpatient Monitoring & Early Warning Scores
**Event Type:** *Critical LFT Alert + AMU Deterioration Observation Trigger*
**Location:** Acute Medical Unit (AMU) – Bed 12

---

## **1. Alert Event Summary**

* **System Alert ID:** NC-LFT-20240902-009

* **Patient:** **Sarah Miller** (MRN: SM43850603, 43F)

* **Linked Encounter:**

  * Admission Type: **Emergency – Medical**
  * Date & Time: **2024-09-02 @ 18:22**
  * Admitting Clinician: **Dr. K. Hussain (AMU SHO)**
  * Responsible Consultant: **Dr. A. Bennett (Gastroenterology)**

* **Clinical Presentation:**

  * Nausea, reduced appetite, right upper quadrant discomfort
  * Recent MTX cessation after abnormal LFTs
  * Query **Methotrexate-related DILI vs MASLD flare**

---

## **2. Trigger Details – Critical LFT Alarm**

### **Primary Trigger Rule:**

* **Rule 4.7 – ALT ≥ 5 × ULN OR significant rise since last test.**
* **ALT: 242 U/L** (ULN 40 → **6.05 × ULN**)
* **AST: 198 U/L (H)**
* **ALP: 130 U/L (upper-normal)**
* **GGT: 165 U/L (H)**
* **Total Bilirubin: 26 μmol/L (mild elevation)**
* **Direct Bilirubin: 8 μmol/L**
* **INR: 1.2 (upper-normal, no synthetic failure)**
* **Albumin: 39 g/L (normal)**
* **Platelets: 212 × 10⁹/L**

### **Pattern of Injury:**

* **Marked hepatocellular injury**
* Mild bilirubin elevation (not cholestatic)
* No acute liver failure criteria

### **Severity Level:**

* **Level 4 – Critical Alert (Inpatient)**
* Requires **review within 30 minutes**

### **Medication Linkage:**

* MTX stopped 2 weeks ago
* Patient on **prednisolone 10 mg** for RA flare
* PRN paracetamol (flagged for dosing review)

---

## **3. Early Warning Score (NEWS2) Trigger**

* **NEWS2 Score:** **4** (Yellow)

  * HR 108
  * RR 20
  * Temp 37.8°C
  * SpO₂ 98% RA
  * BP 122/78
* Trigger: “**Physiological change + abnormal blood tests → senior review required**”

### **Observation Alert ID:** NC-OBS-20240902-04

Delivered simultaneously with the LFT alert.

---

## **4. Distribution & Delivery Log**

**Primary Recipients:**

* Dr. Hussain (Admitting SHO)
* AMU Registrar (Dr. Maxwell)
* Gastroenterology On-Call Team
* Medicines Safety Team (due to previous MTX exposure)

**Secondary Recipients:**

* AMU Nurse in Charge
* EWS (NEWS2) Monitoring Dashboard
* Liver Pathway Tracker

### **Delivery Timeline**

1. **18:24:50** – LFTs verified
2. **18:24:55** – Rule 4.7 fired (ALT 242)
3. **18:25:00** – Critical alert sent (Level 4)
4. **18:25:05** – NEWS2 trigger elevated to “Urgent Review”
5. **18:25:10** – On-call Gastroenterology bleeped automatically
6. **18:27:14** – Acknowledged by **Dr. Hussain (AMU SHO)**
7. **18:33:22** – Registrar review documented (Maxwell_J)

---

## **5. Acknowledgment & Escalation Logic**

* **Required Acknowledgement:** Within **30 min**
* **Status:**

  * **Acknowledged – On time (Dr. Hussain @ 18:27)**

### **Escalation process (auto-triggered but closed):**

* **Stage 1 – SHO (5 min)** → Completed
* **Stage 2 – Registrar (15 min)** → Completed
* **Stage 3 – Gastro Consultant (manual if worsening)** → Not required

### **Registrar Safety Note:**

“Likely MTX-related hepatocellular injury, improving bilirubin. Keep NBM for abdominal US, order hepatitis serologies, and trend LFTs q12h.”

---

## **6. Linked Inpatient Tasks (Automatic)**

### **1. NC-TASK-20240902-LFTQ12**

* **Title:** “Repeat LFT + INR every 12 hours”
* **Owner:** AMU Nursing & Phlebotomy
* **Due:** First repeat at **06:00 (03-Sept)**
* **Status:** Open

---

### **2. NC-TASK-20240902-US-LIVER**

* **Title:** “Arrange urgent liver ultrasound”
* **Owner:** Radiology – Priority Queue
* **Due:** Within 24h
* **Status:** Open
* **Notes:** NBM from midnight.

---

### **3. NC-TASK-20240902-VIRAL-AUTOIMMUNE-SCREEN**

* **Title:** “Complete full non-invasive liver screen (viral, autoimmune, metabolic)”
* **Owner:** AMU SHO
* **Due:** 2024-09-03 @ 14:00
* **Status:** Open
* **Pre-populated Notes:**

  * HBV surface antigen
  * HCV Ab
  * ANA, ASMA, AMA
  * Ferritin, transferrin saturation
  * Coeliac serology

---

### **4. NC-TASK-20240902-DILI-REVIEW**

* **Title:** “Consultant Gastro review for suspected DILI”
* **Owner:** Dr. Bennett
* **Due:** Same day (post-ward round)
* **Status:** Pending Consultant signature

---

## **7. Safety & Governance Notes**

* **Policies Applied:**

  * Acute Liver Injury Protocol v4.0
  * DMARD Monitoring (MTX section)
  * NEWS2 Escalation Framework
  * Risk of DILI – high if ALT > 5× ULN

* **System Warnings:**

  * “Recent MTX exposure – evaluate for DILI.”
  * “Trend LFTs closely; risk of progression without synthetic failure yet.”
  * “Investigate MASLD overlap given BMI and T2DM.”

* **Audit Trail (Extract):**

  * 18:25 – Alert created
  * 18:25 – Gastro team notified
  * 18:27 – SHO acknowledgment
  * 18:33 – Registrar review documented
  * 18:34 – LFT-trend monitoring scheduled

---

## **8. Inpatient Liver Monitoring Dashboard Update**

* **Status:** HIGH RISK – Hepatocellular injury
* **Next data refresh:** 12-hourly
* **Outstanding items:**

  * Ultrasound
  * Viral/autoimmune screen
  * Consultant review
  * LFT trend check

**content props dataSource:** Nervecentre
**content props highlights 0 text:** * **ALT: 242 U/L** (ULN 40 → **6.05 × ULN**)
**content props highlights 0 color:** red
**content props highlights 1 text:** AST: 198 U/L (H)
**content props highlights 1 color:** red
**content props highlights 2 text:** GGT: 165 U/L (H)
**content props highlights 2 color:** red
**content props highlights 3 text:** Total Bilirubin: 26 μmol/L (mild elevation)
**content props highlights 3 color:** yellow
**content props highlights 4 text:** Marked hepatocellular injury
**content props highlights 4 color:** red
**content props highlights 5 text:** Level 4 – Critical Alert (Inpatient)
**content props highlights 5 color:** red
**content props highlights 6 text:** Risk of DILI – high if ALT > 5× ULN
**content props highlights 6 color:** red
**content props highlights 7 text:** Recent MTX exposure – evaluate for DILI.
**content props highlights 7 color:** red
**content props highlights 8 text:** Trend LFTs closely; risk of progression without synthetic failure yet.
**content props highlights 8 color:** red
**createdAt:** 2025-11-17T14:00:00.000Z
**updatedAt:** 2025-11-17T14:00:00.000Z